Neuroprotection in vascular dementia

Cerebrovascular Diseases

Volumn 21, Issue SUPPL. 2, 2006, Pages 106-117

  Martínez Vila, Eduardo ^a   Murie Fernández, Manuel ^a   Pérez Larraya, Jaime Gállego ^a   Irimia, Pablo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Neuroprotection of vascular dementia; Vascular dementia; Vascular dementia, prevention; Vascular dementia, treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CANDESARTAN; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CITICOLINE; DIHYDROERGOTOXINE; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NAFTIDROFURYL; NICARDIPINE; NICERGOLINE; NIMODIPINE; OXIRACETAM; PENTOXIFYLLINE; PIRACETAM; POSATIRELIN; RIVASTIGMINE; SEROTONIN 2 ANTAGONIST; SULODEXIDE; THROMBIN INHIBITOR; TRIFLUSAL; UNINDEXED DRUG; WARFARIN; XANTHINE DERIVATIVE;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEVELOPED COUNTRY; DIABETES MELLITUS; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NEUROPROTECTION; OUTCOMES RESEARCH; PHYSICAL DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION;

ANIMALS; CEREBROVASCULAR ACCIDENT; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; EXCITATORY AMINO ACID ANTAGONISTS; GALANTAMINE; HEART DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDANS; MEMANTINE; NEUROPROTECTIVE AGENTS; PATIENT SELECTION; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; STROKE;

EID: 33646490736     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091710     Document Type: Review

References (139)

1. Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-479.
2. Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al: Vascular dementia in a population-based autopsy study. Arch Neurol 2003;60:569-575.
3. Ikeda M, Hokoishi K, Maki N, Nebu A, Tachibana N, Komori K, et al: Increased prevalence of vascular dementia in Japan: a community-based epidemiologjcal study. Neurology 2001;57:839-844.
4. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al: Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(suppl 5): S10-S15.
5. Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E: Incidence of vascular dementia in Rochester, Minn. 1985-1989. Arch Neurol 2002;59:1605-1610.
6. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N: Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology 2003;22:1-12.
7. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30.
8. Meguro K, Ishii H, Yamaguchi S, Ishizaki J, Shimada M, Sato M, et al: Prevalence of dementia and dementing diseases in Japan: the Tajiri project. Arch Neurol 2002;59:1109-1114.
9. Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP: The economical impact of dementia. Presse Méd 2005;34:35-41.
10. Lopez OL, Kuller LH, Becker JT: Diagnosis, risk factors, and treatment of vascular dementia. Curr Neurol Neurosci Rep 2004;4:358-367.
11. Bowler JV, Hachinski V: Vascular dementia; in Ginsberg MD, Bogousslavsky J (eds): Cerebrovascular Disease. Pathophysiology, Diagnosis and Management. Boston, Blackwell Sciences, 1998, pp 1126-1144.
12. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T: Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke 2000;31:2952-2957.
13. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-175.
14. Kalaria RN, Ballard C: Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999(suppl 3):S115-S123.
15. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, et al: Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD. XVIII. Consortium to establish a registry for Alzheimer's disease. Neurology 1998;51:159-162.
16. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA 1997;277:813-817.
17. Bowler JV: Vascular cognitive impairment. Stroke 2004;35:386-388.
18. Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K: Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004;35:1010-1017.
19. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al: Vascular cognitive impairment. Lancet Neurol 2003;2:89-98.
20. Hachinski V: Preventable senility: a call for action against the vascular dementias. Lancet 1992;340:645-648.
21. Hulette C, Nochlin D, McKeel D, Morris JC, Mirra SS, Sumi SM, et al: Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997;48:668-672.
22. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T: Poststroke dementia: clinical features and risk factors. Stroke 2000;31:1494-1501.
23. Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B, et al: Dementia after first stroke. Stroke 1996;27:1205-1210.
24. Desmond DW, Moroney JT, Paik MC, Sano M, Mohr JP, Aboumatar S, et al: Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000;54:1124-1131.
25. Ballard C, Rowan E, Stephens S, Kalaria R, Kenny RA: Prospective follow-up study between 3 and 15 months after stroke: improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. Stroke 2003;34:2440-2444.
26. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996;46:154-159.
27. Fischer P, Gatterer G, Marterer A, Simanyi M, Danielczyk W: Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. Acta Psychiatr Scand 1990;81:551-553.
28. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al: Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol 2000;57:191-196.
29. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436.
30. Brun A: The neuropathology of vascular dementia; in Chiu HC, Gustafson L, Ames D, Holstein MF (eds): Cerebrovascular Disease and Dementia. London, Dunitz, 2000, pp 69-76.
31. Inzitari D, Erkinjuntti T, Wallin A, Del Ser T, Romanelli M, Pantoni L: Subcortical vascular dementia as a specific target for clinical trials. Ann NY Acad Sci 2000;903:510-521.
32. Benson DF, Cummings JL: Angular gyrus syndrome simulating Alzheimer's disease. Arch Neurol 1982;39:616-620.
33. Looi JC, Sachdev PS: Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999;53:670-678.
34. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
35. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
36. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42:473-480.
37. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva, WHO, 1993.
38. Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al: Vascular dementia in a population-based autopsy study. Arch Neurol 2003;60:569-575.
39. Wetterling T, Kanitz RD, Borgis KJ: Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996;27:30-36.
40. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M: Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997;28:785-792.
41. Lopez OL, Kuller LH, Becker JT, Jagust WJ, DeKosky ST, Fitzpatrick A, et al: Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology 2005;64:1539-1547.
42. Lopez OL, Larumbe MR, Becker JT, Rezek D, Rosen J, Klunk W, et al: Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia. Neurology 1994;44:1240-1245.
43. Korczyn AD: The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 2005;229-230:3-6.
44. Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, et al: Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000;59:931-945.
45. Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ: Alzheimer's disease and brain infarcts in the elderly. Agreement with neuropathology. J Neurol 2002;249:1529-1534.
46. Zekry D, Hauw JJ, Gold G: Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc 2002;50:1431-1438.
47. Langa KM, Foster NL, Larson EB: Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004;292:2901-2908.
48. Zekry D, Duyckaerts C, Belmin J, Geoffre C, Herrmann F, Moulias R, et al: The vascular lesions in vascular and mixed dementia: the weight of functional neuroanatomy. Neurobiol Aging 2003;24:213-219.
49. Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, et al: Clinico-neuropathologjcal correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 1999;47:564-569.
50. Breteler MM: Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-160.
51. Meyer JS, Rauch GM, Crawford K, Rauch RA, Konno S, Akiyama H, et al: Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 1999;14:1050-1061.
52. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999;354:919-920.
53. De la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152-1162.
54. Bugiani O: A β-related cerebral amyloid angiopathy. Neurol Sci 2004;25(suppl 1):S1-S2.
55. Goulding JM, Signorini DF, Chatterjee S, Nicoll JA, Stewart J, Morris R, et al: Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia. J Neurol Neurosurg Psychiatry 1999;67:654-657.
56. Zekry D, Duyckaerts C, Moulias R, Belmin J, Geoffre C, Herrmann F, et al: Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol (Berl) 2002;103:481-487.
57. Hachinski V, Munoz D: Vascular factors in cognitive impairment - where are we now? Ann NY Acad Sci 2000;903:1-5.
58. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al: Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124-134.
59. Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T: The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 2000;175:116-123.
60. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D: A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996;19:497-506.
61. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J: Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549-555.
62. Williams PS, Rands G, Orrel M, Spector A: Aspirin for vascular dementia. Cochrane Database Syst Rev 2000(4):CD001296.
63. Lopez-Pousa S, Mercadal-Dalmau J, Marti-Cuadros AM, Vilalta-Franch J, Lozano-Gallego M: Triflusal in the prevention of vascular dementia. Rev Neurol 1997;25:1525-1528.
64. Parnetti L, Mari D, Abate G, Balestreri R, Cucinotta D, Coppola R, et al: Vascular dementia Italian sulodexide study (VADISS). Clinical and biological results. Thromb Res 1997;87:225-233.
65. Adibhatla RM, Hatcher JF, Dempsey RJ: Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 2002;80:12-23.
66. Fioravanti M, Yanagi M: Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2000(2):CD000269.
67. Flicker L, Grimley EJ: Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2000(2):CD001011.
68. Maina G, Fiori L, Torta R, Fagiani MB, Ravizza L, Bonavita E, et al: Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 1989;21:141-145.
69. Schneider LS, Olin JT: Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787-798.
70. Oudart N: Naftidrofuryl inhibits contractions to serotonin in intact and de-endothelialized cerebral arteries in vitro. J Cardiovasc Pharmacol 1990(suppl 3):S45-S48.
71. Moller HJ, Hartmann A, Kessler C, Rainer M, Brown T, Gamand S, et al: Naftidrofuryl in the treatment of vascular dementia. Eur Arch Psychiatry Clin Neurosci 2001;251:247-254.
72. Emeriau JP, Lehert P, Mosnier M: Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clin Ther 2000;22:834-844.
73. Parnetti L, Ambrosoli L, Agliati G, Caratozzolo P, Fossati L, Frattola L, et al: Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs. placebo. Acta Neurol Scand 1996;93:456-463.
74. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327-1332.
75. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297-303.
76. Van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG: The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183-1194.
77. Herrmann WM, Stephan K, Gaede K, Apeceche M: A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 1997;8:9-17.
78. Bes A, Orgogozo JM, Poncet M, Rancurel G, Weber M, Bertholom N, et al: A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg/day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313-322.
79. Fioravanti M, Flicker L: Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001(4):CD003159.
80. Tomimoto H, Akiguchi I, Ohtani R, Yagi H, Ogura S, Wakita H: Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease. Intern Med 2000;39:966-969.
81. Schuff-Werner P, Schutz E, Seyde WC, Eisenhauer T, Janning G, Armstrong VW, et al: Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 1989;19:30-37.
82. Walzl M: A promising approach to the treatment of multi-infarct dementia. Neurobiol Aging 2000;21:283-287.
83. European Pentoxifylline Multi-infarct Dementia Study. Eur Neurol 1996;36:315-321.
84. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP: Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 1992;40:237-244.
85. Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S166-S171.
86. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I: Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord 1998;9(suppl 1): 36-43.
87. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-1839.
88. Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297-305.
89. Mobius HJ, Stoffler A: New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis 2002(suppl2):61-66.
90. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-1290.
91. McKeith I: Galantamine for vascular dementia. Lancet Neurol 2002;1:210.
92. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV: An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765-1782.
93. Moretti R, Torre P, Antonello RM, Cazzato G: Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361-362.
94. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203-204:141-146.
95. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-486.
96. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-2330.
97. Schneider LS: Cholinesterase inhibitors for vascular dementia? Lancet Neurol 2003;2:658-659.
98. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al: Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population-based study. BMJ 2001;322:1447-1451.
99. Haan MN, Wallace R: Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004;25:1-24.
100. Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA: Stalins and the risk of dementia. Lancet 2000;356:1627-1631.
101. Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA: Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001;161:152-156.
102. Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759-1766.
103. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke 1998;29:75-81.
104. Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, Tatemichi TK: Risk factors for incident dementia after stroke. Role of hypoxic and ischemic disorders. Stroke 1996;27:1283-1289.
105. Bornstein NM, Gur AY, Treves TA, Reider-Groswasser I, Aronovich BD, Klimovitzky SS, et al: Do silent brain infarctions predict the development of dementia after first ischemic stroke? Stroke 1996;27:904-905.
106. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
107. De Groot JC, De Leeuw FE, Oudkerk M, Van Gijn J, Hofman A, Jolles J, et al: Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002;52:335-341.
108. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR: Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217-1225.
109. Schmidt R, Schmidt H, Fazekas F: Vascular risk factors in dementia. J Neurol 2000;247:81-87.
110. Hack W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, et al: European Stroke Initiative Recommendations for Stroke Management - Update 2003. Cerebrovasc Dis 2003;16:311-337.
111. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780-786.
112. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274:1846-1851.
113. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
114. Skoog I: Risk factors for vascular dementia: a review. Dementia 1994;5:137-144.
115. Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF: Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000;31:1487-1493.
116. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA: Current and remote blood pressure and cognitive decline. JAMA 1999;281:438-445.
117. Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS, et al: Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African-Americans. Arch Intern Med 2002;162:2090-2096.
118. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42-48.
119. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-1351.
120. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046-2052.
121. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
122. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-1075.
123. Reitz C, Tang MX, Luchsinger J, Mayeux R: Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705-714.
124. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, et al: APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531-1538.
125. Yaffe K, Barrett-Connor E, Lin F, Grady D: Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378-384.
126. Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, et al: Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254-260.
127. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263-276.
128. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C: Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995;18:209-214.
129. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al: Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047-1051.
130. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
131. Collins R, Armitage J, Parish S, Sleight P, Peto R: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
132. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630.
133. Suribhatla S, Dennis MS, Potter JF: A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 2005;229-230:147-150.
134. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, et al: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 2002;14:239-248.
135. Guo Z, Viitanen M, Fratiglioni L, Winblad B: Low blood pressure and dementia in elderly people: the Kungsholmen Project. BMJ 1996;312:805-808.
136. Zuccala G, Onder G, Pedone C, Carosella L, Pahor M, Bernabei R, et al: Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology 2001;57:1986-1992.
137. Ryglewicz D, Rodo M, Kunicki PK, Bednarska-Makaruk M, Graban A, Lojkowska W, et al: Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002;203-204:195-197.
138. Masaki KH, Losonczy KG, Izmirlian G. Foley DJ, Ross GW, Petrovitch H, et al: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265-1272.
139. Sobrado M, Roda JM, Lopez MG, Egea J, Garcia AG: Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 2004;365:132-136.